dovitinib tki258 clinical trial intelligence

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Tumor Pathway Activations Inhibited by Dovitinib. SEO and diligence focus: Dovitinib (TKI258), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by target_normalized: Dovitinib (TKI258)